Shanghai Fosun Pharmaceutical (600196.SH): The approval to conduct Phase I clinical trials for the treatment of advanced/metastatic solid tumors with HLX97.
Fosun Pharma (600196.SH) announced that its controlling subsidiary, Shanghai Fosun Hanlin Biotech Co., Ltd. and its controlled subsidiary (collectively "Fosun Hanlin") have received approval from the National Medical Products Administration to conduct Phase I clinical trials for HLX97 (a KAT6A/B small molecule inhibitor) for the treatment of advanced/metastatic solid tumors. Fosun Hanlin plans to conduct related clinical studies for this drug in China once the conditions are met.
Shanghai Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary Shanghai HENLIUS Biotech Co., Ltd and its holding subsidiaries (collectively "HENLIUS") have received approval from the National Medical Products Administration to conduct Phase I clinical trials for HLX97 (KAT6A/B small molecule inhibitors) for the treatment of late-stage/metastatic solid tumors. HENLIUS plans to conduct relevant clinical studies of the drug in China after meeting certain conditions.
Related Articles
CHINA HK POWER (00931) plans to issue 722 million shares of capitalization shares.
SINOFORTUNE FIN (08123) plans to carry out a share capital restructuring and change in the minimum trading unit per lot.
On March 5th, NetEase Music (09899) spent HK$14.9929 million to repurchase 103,300 shares.
CHINA HK POWER (00931) plans to issue 722 million shares of capitalization shares.
SINOFORTUNE FIN (08123) plans to carry out a share capital restructuring and change in the minimum trading unit per lot.
On March 5th, NetEase Music (09899) spent HK$14.9929 million to repurchase 103,300 shares.
RECOMMEND
